Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

NCT05730595 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2023-08-29

No results posted yet for this study

Summary

To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.

Conditions

  • Colorectal Neoplasms
  • Fluorescence
  • Lymph Node Excision

Interventions

PROCEDURE

lymph node dissection

The extent of lymph node dissection varies between groups

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER
  • Fujian Province Tumor Hospital

    collaborator OTHER
  • Guangdong Provincial People's Hospital

    collaborator OTHER
  • Shengjing Hospital

    collaborator OTHER
  • Affiliated Hospital of Qinghai University

    collaborator OTHER
  • Hebei Medical University Fourth Hospital

    collaborator OTHER
  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER
  • Jiangxi Provincial Cancer Hospital

    collaborator OTHER
  • The First Hospital of Jilin University

    collaborator OTHER
  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER
  • Shanxi Province Cancer Hospital

    collaborator OTHER
  • Nanfang Hospital, Southern Medical University

    collaborator OTHER
  • Second People's Hospital of Yunnan Province

    collaborator OTHER
  • Binzhou Medical University

    collaborator OTHER
  • The First Affiliated Hospital of University of Science and Technology of China

    collaborator OTHER
  • First Affiliated Hospital of Chengdu Medical College

    collaborator OTHER
  • The Second People's Hospital of Yibin

    collaborator OTHER
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2026-12-01
Completion
2027-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05730595 on ClinicalTrials.gov